ESTRO Annual Report 2018

First page Table of contents 1 Next page Last page

A n n u a l R e p o r t

table of contents

Editorial

Mission

MeMbeRship Profile of ESTROmembers | 8 Main benefits of membership | 10 Structured and diversified membership categories | 11 Membership categories under the spotlight | 12

science disseMinAtion Meetings | 22 Publications | 46 ESTRO and research | 64 Guidelines | 70

estRo school Live courses | 75 Pre-meeting courses | 81 E-learning | 83 Strategic milestone | 88

public AffAiRs Health Economics in Radiation Oncology (HERO) | 92 National societies | 94

Patients | 95 Industry | 97 Members | 97

Other oncology societies | 98 Radiation Oncology Safety and Quality Committee (ROSCQ) | 101

103

109

113

the estRo cAnceR foundAtion The Marie Curie legacy

Financial report

Annex

campaign | 105 Super Run | 107

Editorial 2018 annual report

This ESTRO Annual Report highlights the Society’s standout achievements in 2018. We hope you enjoy reading it. In this editorial, we turn the spotlight onto a few of these accomplishments. In 2018 the Society’s leadership led a retreat in Mechelen, Belgium, to develop the new ESTRO Vision and strategy, which will guide us through to 2030, when the first Vision comes to an end in 2020. The ESTRO Vision 2030 – “Radiation oncology. Optimal health for all, together” – will be published in Radiotherapy & Oncology this year in July. In this report we highlight the main strategic points in the new Vision. The ESTRO membership is the heart of our Society. In terms of numbers, we can now boast 7,656 radiation oncology professional members from across the world. The ever-increasing membership is a testament to the much sought- after portfolio of activities that we offer. This portfolio includes our long track-record of organising conferences, disseminating the latest findings and providing a platform for networking. In 2018, our annual congress, ESTRO 37 was held in Barcelona, Spain, and yet again saw a steady increase in participation at both individual and industry level. Also in 2018, ESTRO and its Asian partners held the first conference of its kind: the ‘ESTRO meets Asia’ congress, a collaborative effort to bring together radiation oncologists in Europe and Asia. We held a number of other collaborative meetings in Europe with other oncology societies on topical / organ-based and non- organ-basedmultidisciplinary subjects. All these meetings underscore the interdisciplinary and

multidisciplinary approaches that hold the key to improving cancer patient care. Closer tohome, our physicists andbrachytherapists held successful workshops. This is another platform that ESTRO continues to encourage, facilitating scientific and professional networking opportunities within ESTRO’s sub-specialties. The Society’s flagship journal, Radiotherapy & Oncology, and the three open-access journals – Clinical and Translational Radiation Oncology (ctRO), Physics and Imaging for Radiation Oncology (phiRO), and Technical Innovations and Patient Support in Radiation Oncology (tipsRO) – all saw an increase in online usage in 2018. You can read more about them and other ESTRO publications in this annual report. The ESTRO School’s catalogue of courses is continuously improved and developed to ensure the quality of its of courses, which range from face- to-face courses at both basic and advanced levels, to online courses, depending on professional development needs. In 2018, ESTRO offered 33 courses, 27 in Europe and six outside. The impressive portfolio is a direct response to the needs of members and trends in technology. In 2018, the collaboration between ESTRO, the Canadian Association of Radiation Oncology (CARO) and the Royal Australian and New Zealand College of Radiologists (RANZCR) culminated in the creation of a new blended- learning course on leadership, designed to fill a gap in radiation oncology training that has become increasingly apparent over recent years. Through its wide range of public affairs activities, ESTRO is nowwell established in promoting the

editorial

mission

The mission of ESTRO, a non- profit, scientific organisation, shall be to foster, inall its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology. To fulfill its mission ESTRO will: • Develop and promote standards of education in radiotherapy and clinical oncology • Promote standards of practice in radiotherapy, clinical oncology and related subjects • Stimulate the exchange of scientific knowledge in all related fields • Strengthen the clinical specialty of radiotherapy and clinical oncology in relation to other specialties and professions involved in cancer management • Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects • Facilitate research and development in radiotherapy, clinical oncology and related subjects.

understanding of radiation oncology to policy communities at the European level, ensuring that high-quality information and evidence is made available to influence long-term political strategies. In 2018, the ESTRO Cancer Foundation (ECF) media campaigns on the Marie Curie Legacy, which are designed to raise awareness of the benefits of radiotherapy in curing cancer, were successfully delivered in five European countries – Poland, Spain, Italy, Germany and Portugal. This involved close collaboration with national societies and capitalising on notable cancer- related activities. We end by acknowledging the vital support that the Society receives frommembers who volunteer and commit to developing ESTRO activities to the standard for which they are well known. One cannot overlook the constant support we receive from the ESTROoffice, our industry partners and other organisations that we collaborate with, both in Europe and around the world. We also thank the many ESTRO members who supported the Society by attending ESTRO activities during the year. Without your participation ESTRO would not be able to carry out the work that is needed to ensure the growth and development of the profession of which we are so proud, ultimately to deliver optimal care to cancer patients in Europe and beyond.

Best wishes

Umberto Ricardi ESTRO President

editorial

ESTROVISION 2030 Radiation oncology has seen considerable change since ESTRO adopted its previous vision statement, less than 10 years ago. ESTRO has now formulated a new vision for 2030, which remains dedicated to its mission, whilst adapting to evolving contexts and the transforming landscape. Aligning with the new vision, ESTRO has developed strategic priorities for the coming years. ESTRO’s new vision statement for 2030 ‘Radiation Oncology. Optimal Health for All, Together.’ emphasizes the ambition of the Society to further reinforce radiation oncology as core partner in multidiscipinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. To do so, ESTROwill actively focus on translating science and evidence into practice. It will continue to support all radiation oncology professionals in their requirements of continuous professional development. The necessities of a growing Society in terms of governance and leadership will actively be addressed. The Society will also increasingly embrace its role in policy, through a broadening network of partnerships with all relevant stakeholders. Without calling for a disruptive change with the past, but conscious of the challenges ahead, the ESTRO vision statement for 2030 is ambitious, expansive, inclusive and open to the future.

Radiation Oncology. Optimal Health for All, Together. (ESTRO vision, 2030: published ahead of print https://doi.org/10.1016/j.radonc.2019.03.031)

MEMBERSHIP

MEMBERSHIP With nearly 7312 radiation oncology professionals from across the world, the ESTROmembership is the heart of our organisation. In 2018, ESTRO continued to attract new members and engage existing members by giving them the resources and tools they need to successfully navigate a career in radiation oncology and its related fields. From support for professional development to even greater access to scientific information, the membership programme is focused on giving members more of what they need and want.

membership MEMBERSHIP

Profile of ESTROmembers

111 countries

7312 members in 2018

Five continents

Geographical distribution of ESTROmembers

TOP 10 MEMBER COUNTRIES

Switzerland USA Canada Australia Belgium Spain Italy UK Germany The Netherlands 1 5 9 3 7 2 6 10 4 8

75% Europe 7,5% Asia 9% America 6,5% Oceania 2% MED

membership

BREAKDOWN OF ESTROMEMBERS BY SPECIALTY

52,10% Radiation oncologists

10,03% RTTs – nurses – dosimetrists 22,63% Medical physicists 7,02% Clinical oncologists 1,19% Industry representatives 1,5% Radiobiologists 5,53% Other medical and non-medical specialties

The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions. This includes professionals from: • other medical fields related to oncology, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists • non-medical fields, such as public affairs specialists.

EVOLUTION OF MEMBERSHIP

7,312

7,281

6,635 6,742

5,622 5,830

increase of 30% in five years

2013 2014 2015 2016 2017

2018

membership

ESTRO contributes to the day-to-day practiceandcareeradvancementofoncology professionals through the dissemination of the latest research findings and knowledge.

MAIN BENEFITS OF MEMBERSHIP

ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their level of involvement within the Society. The full range of ESTRO membership benefits includes:

Belonging to a community of around 7,312 radiation oncology professionals

Online subscription to Radiotherapy & Oncology , the Society’s journal

Networking opportunities and reduced fees for attending ESTRO teaching courses, online courses, workshops and conferences

Online access to scientific material, including event webcasts and delineation cases through the ESTRO electronic library (DOVE)

Eligibility for grants and awards

Eligibility for ESTRO faculties and governance positions.

membership

STRUCTURED AND DIVERSIFIED MEMBERSHIP CATEGORIES

37,13% full membership - 2715 4,693 individual members

64,18%

38% active - 2.716

0,53% supporting ambassador - 39

26,52% associate membership - 1.939

5,88% in training - 430 0,72% honorary - 53 19,91% affiliate - 1.456

7.312 members in 2018

741 dual and young dual members

10,13%

11 national societies

1,449 institutional members

19,82%

50 institutes

210 corporate members

2,87%

35 companies of which 10 gold and 25 regular members

219 RTT Alliance members

19 national societies

Individual membership:

Institutional membership

Full membership: • Active €95 for one year - €170 for two consecutive years • Supporting ambassador €250 for one year - €450 for two consecutive years • Emeritus

Dual and young dual membership

Corporate membership

RTT Alliance

Associate membership: • In training - €75 • Affiliate - €55 • Corporate representative - €55 • Honorary

*all prices above include VAT

membership

MEMBERSHIP CATEGORIES UNDER THE SPOTLIGHT

1. Institutional membership

The institutional membership category is designed to help European hospitals, clinics or other institutions providing radiotherapy and cancer treatment to develop and support their in- house radiotherapy

50 institute members in total (see annex for list)

1,449 employees supported through this membership category

10 new institutional members in 2018

This category allows institutes to pay a single fee for individual membership on behalf of their employees who can enjoy all the usual advantages of individual membership. The institutions themselves receive a range of benefits, including: • A dedicated institutional Corner in the newsletter, with the possibility of regularly covering developments at the institu- tion • A dedicated institutional webpage on the ESTRO website • Free online job postings • A monthly ESTRO Public Affairs newsletter sent exclusively to all institutional members • An ESTRO institutional member logo, which can be used by the institute on their website, and in scientific presentations alongside their own logo • A free booth in the ESTRO 37 Communities Pavilion in Vienna.

and oncology professionals.

membership

BREAKDOWN OF THE INSTITUTIONAL MEMBERSHIP

50 institutes

23% in training 66% active 8% affiliate 3% supporting ambassador

1,449 institutional members

New institutional members in 2018

Switzerland Kantonsspital Graubünden

Germany Klinikum rechts der Isar, TU Munich

Spain • Instituto Catalan de Oncologia • Hospital Universitario Doce de Octubere

GEORGIA Radiaton Medicine Center

hungary Radiochirurgia Zagreb

France Institut Curie Ensemble Hospitalier

italy • Ospedale S. Pietro Fatebenefratelli • University of Florence

Portugal Quadrantes- Clinica Medica e Diagnostico

membership

2. Supporting ambassador members

This category is reserved for professionals in the field of radiation oncology who are strongly committed to the Society and who want to contribute to the Ambassador Solidarity Fund. The additional income generated goes towards

Who benefits from the Ambassador Fund? The Fund enables sponsorship of educational grants, individual membership and registrations to ESTRO courses or events to help radiation oncology professionals from European countries facing more difficult economic situations (conditions apply).

In 2018, 80 individuals signed up as supporting ambassadors.

the Ambassador Solidarity Fund .

In 2018, educational grants awarded by the Ambassador Solidarity Fund helped:

6 course participants selected by local course organisers received a course registration and an affiliate membership

10 course participants were funded to attend an ESTRO course.

Participants at ESTRO 37 - Nine applicants received:

free registration

free in-training 2018 membership

membership

3. In-training members and young scientists

The younger generation is the Society’s future and therefore it is essential for ESTRO to involve our young members in all of the Society’s activities, from the more basic to the strategic. The young members include young professionals up to the age of 40. ESTRO also continues to develop its collaborations with European societies representing young members to encourage more young radiation oncology professionals to join the Society. We also offer a dual membership tailored to these societies with a range of benefits.

Breakdown of youngmembers:

38% - 325 Individual in-training members 50% - 430 institutional in-training members 12% - 107 young dual members who get the same benefits as an ‘in-training member’

862 young members

membership

Examples of the RESPONSIBILITIES of young ESTROmembers

THE YOUNG CORNER in the ESTRO newsletter. Each issue contains a dedicated young section, coordinated by two young editors with news from young national societies, and young members sharing their experience through meetings or travel grants reports etc.

THE YOUNG FACEBOOK PAGE with more than 2,300 ‘likes’, the young Facebook page is handled by the young committee and focuses on topics of interest to young radiation oncology professionals.

THE YOUNG track is an all-day session held during ESTRO’s annual scientific meeting, which focuses specifically on topics of interest to young professionals.

membership

4. Dual Membership

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non–European national society or a European young national society active in the field of radiation oncology.

In 2018 we concluded one new dual membership agreement with: Iranian Society of Clinical Oncology (ISCO)

5. Corporate membership

Companies can opt for either ESTRO’s regular or gold corporate membership. Gold membership gives the right to a seat on the ESTRO corporate council, which works to facilitate collaboration and coordination between industry’s research and development activities, and the academic and scientific developments within ESTRO.

10 gold members 25 regular members

35 corporate members

membership

Science Dissemination

science Dissemination

Science Dissemination

Aswell as including events organised byESTRO, this section also covers events organised in association withother partners, and those supported byESTRO.

meetings

1. ESTRO annual congress: ESTRO 37 20-24April 2018 | Barcelona, Spain

ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking.

A comprehensive programme The state-of-the-art scientific programme is developed by expert members of the congress’ various scientific advisory groups, who all work on a voluntary basis. The programme covered all aspects of radiation oncology, featuring presentations from clinicians, medical physicists, radiobiologists, brachytherapists and radiation therapists.

Networking There were multiple opportunities to network at ESTRO 37, including at the 10,000m2 exhibition space, the communities pavilion and start-up corner, and social activities such as the welcome reception, poster awards ceremony, the Super Run and the social event…

Many educational activities The educational programme included pre-meeting courses, teaching lectures, tumour board and contouring sessions. You can read about the educational programme in the School section of this report.

Young programme A whole day was dedicated to ESTRO’s young audience, which included a teaching lecture, symposia and networking activities.

Science Dissemination

4,856 participants

6,211 participants

in cluding 1,355 company delegates

77% European

100 COUNTRIES represented

23% non-European

Science Dissemination

participation

participants per specialty

44,7% radiation oncologists 28,1% medical physicists 4,5% clinical oncologists 11.4% RTTs, RT nurses

3,2% other non-medical specialities

2,5% radiobiologists

breaKdoWn per specialtY breakdown per specialty

2,2% other medical specialities

1.4% dosimetrists

1,1% computer scientists 0.80% RO industry - corporate

0.1% quality manager

geographic overview

Europe: 76,6%

Middle East: 1,8% South America: 1,3% North America: 6.90% Asia and Oceania: 12.8%

Africa: 0.5%

Science Dissemination

participants per country - top 10

The Netherlands: 459

UK: 400

Spain: 303

Germany: 268

Italy: 242

France 224

Belgium: 180 USA: 183

Switzerland: 135 Australia: 142

Evolution

number of participants at the ESTRO Annual Conference (From 2013 to 2018)

ESTRO 33: 5,030

3,727 participants and visitors

1,303 company delegates

3rd ESTRO Forum: 4,933

3,496 participants and visitors

1,437 company delegates

ESTRO 35: 5,284

4,065 participants and visitors

1,219 company delegates

ESTRO 36: 5,860

4,333 participants and visitors

1,527 company delegates

ESTRO 37: 6,211

4,856 participants and visitors

1,355 company delegates

Science Dissemination

Scientific programme

ABSTRACTS - Disciplinary breakdown

Clinical: 1.082 Physics: 895

RTT: 209

2,477 submitted abstracts

Brachytherapy: 141 Radiobiology: 150

abstract submitted

3rd ESTRO Forum: 1,637 ESTRO 33: 1,737

ESTRO 35: 2,200

ESTRO 36: 1,955

ESTRO 37: 2,477

Science Dissemination

294 oral presentations

2477 posters

108 poster viewings

1,303 e-posters

289 invited speakers

Science Dissemination

awards

6 poster awards

3 honorary member awards

5 award lectures

4 company awards

1 university award

5 lifetime achievement awards

6 people benefited from a company travel grant (sponsored by Elekta Brachytherapy) to attend ESTRO 37

9 participants benefited from a free registration financed by the ESTRO solidarity fund

EDUCATION

562 participants attended the 7 pre-conference courses

261 participants attended the 8 contouring workshops

Science Dissemination

EXHIBITION AND INDUSTRY

5,401m 2 sold

117 exhibitors

13 commercial satellite symposia were hosted

number of exhibiting companies at the ESTRO Annual Conference Evolution

3rd ESTRO Forum: 89 ESTRO 33: 105

ESTRO 35: 103

ESTRO 36: 123

ESTRO 37: 117

Science Dissemination

1.2 ESTROMEETS ASIA 7-9December 2018 | Singapore

First of its kind, the ESTRO meets Asia congress has the objective to bring radiation oncology collaboration between Europe and Asia to a new level.

829 participants

289 submitted abstracts

38 countries represented

42 sessions

34 companies

6 national societies

66 contributors

Science Dissemination

PARTICIPANT DISCIPLINE BREAKDOWN

RO: 43,9 RTT: 28,0 Phys: 14,6

ClinOnc: 6,1 Other: 5,5 Dosi: 1,3 RadBio: 0,7

134 submitted abstracts

participants per country - top 10 Howmany participants per country (top 10):

Singapore 100

Australia: 84

Japan: 43 India: 68

Philippines: 29 USA: 29 Hong Kong (SAR) China: 30 Indonesia: 30 Thailand: 37 China: 37

Science Dissemination

2. Topical / organ-based conferences

2.1 ESTRO and joint multidisciplinary events

EMUC’s mission is to improve the care of patients with urological malignancies by fostering education and knowledge exchange in urological oncology through regular international multidisciplinary meetings where insights, best practices and prospects are discussed and examined in a comprehensive and critical manner by opinion leaders. ESTRO is one of the members of the organising steering committee for these meetings. As part of the meeting, ESTRO held a contouring workshop on ‘Post-operative radiotherapy in prostate cancer.’ that had 2.1.1 European Multidisciplinary Congress on Urological Cancers (EMUC) Implementing multidisciplinary strategies in genito-urinary cancers 8-11 November 2018 | Amsterdam, The Netherlands Jointly organised by ESTRO, ESMOand EAU

113 invited speakers

21 participants.

1325 delegates

66 countries

227 abstracts submitted, 180 accepted, 47 rejected, 6 selected for oral presentations

Science Dissemination

participants per country - top 10 GEOGRAPHIC BREAKDOWN OF THE PARTICIPANTS EMUC 2018 - Delegates per country

The Netherlands: 180

Algeria: 36 Slovakia: 41 United Kingdom: 47 Portugal: 47 Spain: 64 Greece: 66 Belgium: 72

Austria: 31 Finland: 33

Science Dissemination

2.2 ESTRO workshops

2nd ESTRO Physics Workshop: Science in Development 26-27October 2018 | Malaga, Spain

The 2 nd ESTROphysics workshop aimed to strengthen scientific and professional networking among ESTRO members with interests in a common area, and to promote ‘out-of-the-box’ thinking. This was facilitated by the small format of the meeting. Five tracks ran in parallel: • Strategies for patient specific QA pre-treatment or in vivo • Predictive models of Toxicity in RT • Improving range accuracy in particle therapy • Realtime and adaptive management of anatomical variations • Quantitative imaging for treatment planning The meeting aimed to outline the latest research, to promote collaboration between different groups and to enable ESTRO members working in the same field to share experiences. 92% of the participants reported that the meeting had expanded their network and that it was very relevant to their work / research and clinical practice.

169 participants

4 NUMBER EXHIBITING COMPANIES

Top 10 countries

The Netherlands: 25

Germany: 18 UK: 25

Sweden: 15

Switzerland: 6 Italy: 8 Belgium: 8 France: 10 Denmark: 11 Spain: 15

Science Dissemination

6th GEC*-ESTRO workshop The strength of brachytherapy 29 - 30November 2018 | Brussels - Belgium

The aim of the workshop was to support the brachytherapy community in their ongoing work to identify common issues in their field and to exchange experiences. The workshop covered the following topics: • BRAPHYQS: TPS-commissioning and Pre-treatment QA • UroGEC: Post TURP and Salvage • ANORECTAL & SKIN: Optimal brachytherapy for skin and anorectal cancers • BREAST: How to perform best multicatheter implant • GYNAE: Brachytherapy in endometrium cancer and upcoming GEC ESTRO recommendations in cervix cancer Each working group had the opportunity to present their ongoing projects. The workshop also enabled GEC-ESTRO members and other attendees interested in brachytherapy to network.

Age breakdown of participants (%)

<30: 22% 31-40: 50% 41-50: 54% ≥50: 43% 44-49: 14.5%

189 participants

Unspecified: 20%

NUMBER OF EXHIBITING COMPANIES : 4

92% of the participants reported that the meeting had expanded their network and that it was very relevant to their work / research and clinical practice.

Science Dissemination

2.3 Events in scientific collaboration with ESTRO

European Breast Cancer Conference (EBCC-11)

21-23 march 2018

Barcelona, Spain

European Lung Cancer Congress (ELCC)

11-14 APRIL 2018

GENEVA, SWITZERLAND

ESHO 2018: 32nd Annual meeting of the European Society for Hyperthermic Oncology www.esho.info

16-19 MAY 2018

Berlin, Germany

ECCO 2018: European cancer summit www.eccosummit.eu

7-9 SEPTEMBER 2018

VIENNA, AUSTRIA

Perspectives of Advanced Radiotherapy in Middle Income Countries http://cong2018.isro.org.ir

26-28 SEPTEMBER 2018 TEHERAN, IRAN

European Breast Cancer Conference (EBCC-11) 21-23March 2018 | Barcelona, Spain

The 11th European Breast Cancer Conference (EBCC-11) hosted by Europa Donna, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Breast Cancer Specialists (EUSOMA) was held at the end of March 2018 at the CCIB conference centre in Barcelona, Spain. EBCC-11 once again took place in the context of very tangible advances made for patients in prevention, diagnosis, treatment and survivorship, and of advances driven by research in recent years, emphasising the successful application of a multidisciplinary approach. This year’s conference was firmly based on an inclusive vision of breast cancer, and brought together a diverse group of clinicians, scientists, patient representatives and health professionals to tackle key issues facing patients throughout the breast cancer journey. The programme highlighted the importance of teamwork and interactions between all professionals and specialties involved in breast cancer treatment.

Science Dissemination

European Lung Cancer Conference (ELCC) 2018 11-14 april 2018 | Geneva, Switzerland

The 8th Edition of the European Lung Cancer Congress (ELCC) was organized by European Society for Medical Oncology (ESMO) and International Association for the Study of Lung Cancer (IASLC) and was held in April 11 - 14, 2018 at Palexpo, Geneve, Switzerland. The congress has multiple objectives which make it attractive to professionals working in the lung cancer discipline. These are to advance the quality of lung cancer treatment by updating lung cancer and other thoracic oncology specialists on different multidisciplinary topics important for clinical practice; to discuss the increasing understanding of molecular biology and immunology of lung tumours and how it changes the diagnostic and treatment landscape; and to present the latest advances in translational and clinical research in different settings across lung and other thoracic malignancies.

32nd Annual Meeting of the European Society for Hyperthermic Oncology 16-18may 2018 | Berlin

The scientific focus of the ESHO2018meeting was multimodal treatment of abdominal tumors involving thermal therapy – potential and caveats. A line-up of world class speakers as well as interdisciplinary congress sessions contributed to attract clinicans from various oncological specialities and from around the world.

Science Dissemination

ECCO2018: European Cancer Congress - From science to real-life oncology 7-9 September 2018 | Vienna, Austria

Over 350 experts and leaders from across the cancer care stakeholder communities met at the ECCO 2018 European Cancer Summit during the Austrian EU Presidency in Vienna on 7-9 September. They decided on how Europe can improve the ways by which quality of cancer care is measured, integration of cancer care is made reality, and how financial discrimination experienced by survivors of cancer can be alleviated.

The three high-level, time-based goals, passed as resolutions by the Summit were:

1. By 2023, an agreed set of core standards and evidence-based indicators (based on processes and patient outcomes) to measure the quality of all cancer services in European countries should be in place. 2. By 2025, all national cancer plans in Europe should contain ambitious and measurable goals and actions to improve the integration of primary care professionals and informal carers within the multidisciplinary care given to patients. 3. By 2025, in respect to accessing financial services*, the right of cancer survivors not to declare their cancer ten years after the end of the active treatment**, and five years if they had cancer under the age of 18, should be codified across European countries. A set of defined actions will transpose the resolutions into practice. The complete list of resolutions and supporting actions are available at www.eccosummit.eu/Resolutions

Perspectives of Advanced Radiotherapy in Middle Income Countries 26-28 September 2018 | Tehran, Iran

The advent of multileaf collimators in 90s and the ever increasing access to fast computers laid the foundation for a radical change in the practice of radiation therapy. Advanced technology emerged together with numerous conceptual and technical ramifications in treatment calculation and delivery. Merged with imaging, advanced radiotherapy in developed countries has become much resource- intensive, team-based and complex; nevertheless, it is now the new norm. Modern treatment technology is inevitably – though not comprehensively– finding its way to the clinics of many developing countries, where the industrial work culture and technical network has not yet flourished as much. In developing countries, especially where private practice is allowed, there is a vibe towards purchasing fancier technologies to get a lead against other radiotherapy centres and potentially attract more patients as a result of selling the prestige of the new technology. The conference was programmed by ISCO, in scientific collaboration with ESTRO and benefitted from a world-class faculty in the field of radiation oncology.

Science Dissemination

2.4 Endorsed meetings

In addition to the meetings listed above, in which ESTRO joined or participated in the scientific organisation, the Society also helps to promote meetings organised by other societies, institutes or partners in the oncology community. In 2018, ESTRO supported 31 such meetings. Once their application is approved by the ESTROBoard, all of these meetings benefit from a relevant promotional package, including visibility on the ESTRO website and in the newsletter.

Independent Data Monitoring Committee (IDMC) Interactive Workshop www.eortc.org/event/idmc- interactive-workshop/ 9th Canadian Winter School www.comp-ocpm. ca/2018-winter-school/ Think tank meeting on research challenges in breast cancer 2018 www.radioterapiaitalia.it/wp-content/ uploads/2017/10/FULL-PROGRAM-THREE-DAYS. pdf 4th conference on Small Animal Precision Image Guided Radiotherapy small-animal-rt-conference. com/program/ Irish Annual SRS/SABR symposium www. futurehealthsummit.com/cth_schedule/annual- irish-stereotactic-radiosurgery-stereotactic-body- radiotherapy-symposium-4 Next Gen Immuno-Oncology congress events. marketsandmarkets.com/2nd-Annual-Next-Gen- Immuno-Oncology-Congress#Home MCCR - Methods in Clinical Cancer Research Workshop www.ecco-org.eu/Events/MCCR- Workshop Global Congress on Prostate Cancer 2018 http:// prosca.org AAPM-ISEP: Challenges in Modern Radiation Therapy Physics course www.aapm-isep.si 2nd International Conference on Head and Neck Cancer IMRT and VMAT planning in practice at ECMP2018 ecmp2018.org/fileadmin/user_upload/ ECMP_2018/IMRT_VMAT_planning_in_practice. pdf Bucharest Oncology Summer School http://ssob.ro

26 JANUARY 2018

BRUSSELS, BELGIUM

LAKE LOUISE, ALBERTA, CANADA

11-15 FEBRUARY 2018

1-2 MARCH 2018

ASSISI, ITALY

12-14 MARCH 2018

LISBON, PORTUGAL

28-29 MAY 2018

DUBLIN, IRELAND

13-14 MARCH 2018

LISBON, PORTUGAL

11-15 JUNE 2018

BUCHAREST, ROMANIA

16-22 JUNE 2018

ZEIST, THE NETHERLANDS

28-30 JUNE 2018

FRANKFURT, GERMANY

3-7 JULY 2018

LJUBJANA, SLOVENIA

1-2 AUGUST 2018

TEHERAN, IRAN

22 AUGUST 2018

COPENHAGEN, DENMARK

Breast meeting www.londonbreastmeeting.com

5-8 SEPTEMBER 2018

LONDON, UK London

Science Dissemination

IMRT & VMAT planning in practice at ECMP2018

22 August 2018

Copenhagen, Denmark

2nd international workshop on ultra high dose rate www.chuv.ch XVI TMH Annual Radiotherapy Practicum tmc. gov.in/m_events/Events Arab African International Cancer Congress (AAICC) www.aaicc.net SO masterclass in neuro-oncology, Multidisciplinary management of adult brain tumour www.eso.net/en/education/future/ events/eso-masterclass-in-neuro-oncology:- multidisciplinary-management-of-adult-brain- tumours 14th Meet the Professor Advanced International Breast Cancer Course meettheprofessor.accmed.org 6th Annual UPMC International Symposium on Stereotactic Radiosurgery and Stereotactic Body Radiotherapy www.upmcsanpietro.it/upmc-5th- annual-symposium-of-radiotherapy International conference on immunotherapy radiotherapy combinations 2018 www.radio- immuno.siricsocrate 3rd Symposium on Stereotactic Body Radiation Therapy: From physics to clinic www.symposium. it/en 28th Residential Course on Modern Radiotherapy and unconventional treatments fractionations, volumes and new drugs roma.unicatt.it/20180503_- _28_Course_program.pdf International Marie Sklodowska-Curie Meeting: From Radiation to Innovation in Medicine XXVIII National Congress AIRO 22 NOVEMBER 2018 https://www.airo2018.com BRAVO symposium 2018: Fighting breast cancer with innovative radiotherapy www.bravo- radiotherapie.be/fr/bravo-symposium BLADDR 2018 http://bladdr.org Interdisciplinary oncology - time for modern solutions www.onkologia2018.pl The 3rd World Precision Medicine (China) Summit wpmcs.com.cn Young Scientists Forum 2018 www.wco.pl/ysf2018/en

12-13 SEPTEMBER 2018 LAUSANNE,SWITZERLANDe

15-16 SEPTEMBER 2018 MUMBAI, INDIA

CAIRO, EGYPT

20-21 SEPTEMBER 2018

20-21 SEPTEMBER 2018 MADRID, SPAIN

20-22 SEPTEMBER 2018 MILAN, ITALY

20-22 SEPTEMBER 2018

Padua, Italy

21-22 SEPTEMBER 2018 Berlin, Germany

20-22 SEPTEMBER 2018 PARIS, FRANCE

4-6 OCTOBER 2018

FLORENCE, ITALY

8-10 OCTOBER 2018

ROME, ITALY

12 OCTOBER 2018

PARIS, FRANCE

2-4 NOVEMBER 2018

RIMINI, ITALY

17 NOVEMBER 2018

BRUSSELS, BELGIUM

22 NOVEMBER 2018

POZNAN, POLAND

22-24 NOVEMBER 2018 POZNAN, POLAND

8-9 DECEMBER 2018

SHANGHAI, CHINA

Science Dissemination

Big data imaging bigdata4imaging.info

MAASTRICHT, THE NETHERLANDS

9-12 DECEMBER 2018

Sixth Annual UPMC International Symposium on Stereotactic Radiosurgery and Stereotactic Body Radiotherapy www.estro.org/binaries

14-15 DECEMBER, 2018 Rome, Italy

2.5 Meetings by invitation

Conference on Experimental Research in Radiation Oncology (CERRO) 13-20 January 2018 | LesMenuires, Trois Vallées, France

The 33rd CERRO conference, known popularly as the ‘ski meeting’, was held as per tradition in Les Menuires, Trois Vallées, France, in January. Participation is by invitation, and in this meeting there were 48 delegates from different disciplines in radiation oncology. Presentations on work in progress are the focus of the event, in order to stimulate discussions on innovative research. The meeting is also a platform for promoting collaboration and networking between members and for integrating young members into the Society.

Science Dissemination

publications

This section of the Annual Report is dedicated to ESTRO’s family of four journals: Radiotherapy & Oncology , the Society’s flagship publication, and Clinical & Translational Radiation Oncology (ctRO), Physics & Imaging in Radiation Oncology (phiRO), and Technical Innovations & Patient Support in Radiation Oncology (tipsRO) , which were all launched more recently to provide specialised spaces for the publication of ESTRO members’ work. 1. ESTRO’s family of journals

Science Dissemination

The Green Journal

Radiotherapy & Oncology , known as the Green Journal , is the flagship publication in ESTRO’s family of journals. Led by editor-in-chief, Michael Baumann (Heidelberg, Germany), it covers all aspects of radiation oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.

Manuscript submissions In 2018 there were

Accepted papers: 356 (24%)

Rejection rate: 76%

1,526 submissions*

* an increase of 11% over previous year

Breakdown of submission types

Editorial: 3

Original research: 1,352

Review: 64

Short communication: 70 Letters to the editor: 37

Science Dissemination

Evolution Manuscript submissions

1,526

1,377

1,326

1,299

1,278

1,254

1,249

1,146

1200

900

Numberofarticles submitted

600

Short communications Technical note

Letters to the editor

300

Original research Editorials Review articles

Year

2011

2012

2013

2014

2015

2016

2017

2018

Geographic Distribution of Accepted Papers in 2018

The USA was the country that contributed the largest number of papers in 2018 with 61 accepted papers, followed by The Netherlands (45), Germany (34), China (26), and France (17).

Europe: 197

Australasia: 14 South America: 1 North America: 78 Asia: 66

Science Dissemination

Article transfer service to ctRO , phiRO and tipsRO

For manuscripts deemed not appropriate for publication in Radiotherapy &Oncology , authors may be provided with the option of having their manuscript transferred to an ESTRO OA publication.

Evolution

Impact Factor Trend (2010-2017)

5.580

4.942

Impact factor

4.817

4.857

4.363

4.328

4.520

4.337

Year

2917

2010

2011

2012

2013

2014

2015

2016

2017 impact factor not known yet.

Science Dissemination

Online usage

Online usage of Radiotherapy &Oncology was stable in 2017, withmore than 710,000 downloads.

Evolution

Online Usage: 2010 - 2018

1200

1000

800

600

Science Direct

400

Clinical Key Thegreenjournal.com

200

2011

2014

2015

2016

2017

2018

Year

Geographical distribution of online usage

Western Europe: 34% North America: 28%

Asia: 27%

Eastern Europe: 2% Australasia: 5% South America: 2%

712,979 downloads

Middle East: 1%

Africa: 1%

Science Dissemination